Monitor for Q3 2026 training commencement and any updates on U.S. FDA pivotal study enrollment completion. The stock remains a binary event-driven story tied to FDA approval and commercial adoption — no fundamental catalyst from this filing.
Price Chart
Executive Summary
Regentis announced plans to commence European surgeon training for its GelrinC knee cartilage implant in Q3 2026, advancing commercial launch preparations in the EU where it already holds CE Mark approval. The filing is a routine operational update with no financial data — the company remains pre-revenue with a $7M market cap, and the announcement does not change the fundamental risk profile.
Key Facts
- Regentis plans to commence European surgeon training for GelrinC in Q3 2026 at Humanitas Research Hospital in Milan, Italy.
- GelrinC is CE Mark approved in the European Union and is being evaluated in a U.S. pivotal FDA study that has completed over 50% enrollment.
- The company targets an estimated $3 billion U.S. market of 470,000 annual knee cartilage repair cases.
- No revenue, earnings, or financial guidance figures were provided in this filing.
Financial Impact
No financial figures provided; company is pre-revenue with a $7M market cap.
Risk Factors
- No revenue or near-term commercialization revenue; cash burn continues without disclosed financing runway.
- U.S. FDA approval is not guaranteed; pivotal study enrollment at >50% but completion timeline uncertain.
- Micro-cap liquidity risk with $7M market cap — any news can cause disproportionate price moves.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-066070 |
| Document: ea0293842-6k_regentis.htm | 0001213900-26-066070 |
| Document: 0001213900-26-066070-index-headers.html | 0001213900-26-066070 |
| Document: 0001213900-26-066070-index.html | 0001213900-26-066070 |
| Document: 0001213900-26-066070.txt | 0001213900-26-066070 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.63 | awaiting T+20 | — | $1.27 (−21.85%) |
Sep 23, 2026 4w ago | EFFECT | $2.10 $1.49 | ▼ −29.05% | ▼ −29.74% | $1.27 (−39.52%) |
Jul 20, 2026 14w ago | 6-K | $2.00 $2.04 | ▲ +2.00% | ▼ −2.12% | $1.27 (−36.50%) |
Jul 15, 2026 14w ago | 6-K | $2.43 $1.94 | ▼ −20.16% | ▼ −22.51% | $1.27 (−47.74%) |
Jul 14, 2026 15w ago | EFFECT | $2.54 $1.84 | ▼ −27.56% | ▼ −30.05% | $1.27 (−50.00%) |
Jun 15, 2026 19w ago | 6-K | $9.40 $2.43 | ▲ +74.15% | ▲ +74.15% | $1.27 (+86.49%) |
Jun 9, 2026 20w ago | F-1/A | $2.41 $3.64 | ▲ +51.04% | ▲ +49.59% | $1.27 (−47.30%) |
Jun 8, 2026 20w ago | 6-K | $1.28 $3.58 | ▲ +179.69% | ▲ +178.85% | $1.27 (−0.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers